Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis
Hepatology, Volume 76, No. 1, Year 2022
Notification
URL copied to clipboard!
Description
Background and Aims: HCV cure reduces but does not eliminate the risk of HCC. HCC surveillance is recommended in populations where the incidence exceeds 1.5% per year. In cirrhosis, HCC surveillance should continue after HCV cure, although it is uncertain if this should be indefinite. For patients with advanced fibrosis (F3), guidelines are inconsistent in their recommendations. We evaluated the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. Approach and Results: This systematic review and meta-analysis identified 44 studies (107,548 person-years of follow-up) assessing the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. The incidence of HCC was 2.1 per 100 person-years (95% CI, 1.9–2.4) among patients with cirrhosis and 0.5 per 100 person-years (95% CI, 0.3–0.7) among patients with F3 fibrosis. In a meta-regression analysis among patients with cirrhosis, older age (adjusted rate ratio [aRR] per 10-year increase in mean/median age, 1.32; 95% CI, 1.00–1.73) and prior decompensation (aRR per 10% increase in the proportion of patients with prior decompensation, 1.06; 95% CI, 1.01–1.12) were associated with an increased incidence of HCC. Longer follow-up after HCV cure was associated with a decreased incidence of HCC (aRR per year increase in mean/median follow-up, 0.87; 95% CI, 0.79–0.96). Conclusions: Among patients with cirrhosis, the incidence of HCC decreases over time after HCV cure and is lowest in patients with younger age and compensated cirrhosis. The substantially lower incidence in F3 fibrosis is below the recommended threshold for cost-effective screening. The results should encourage the development of validated predictive models that better identify at-risk individuals, especially among patients with F3 fibrosis. © 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC9303770/bin/HEP-76-139-s001.docx
Authors & Co-Authors
Hajarizadeh, Behzad
Australia, Sydney
Unsw Sydney
Dore, Gregory J.
Australia, Sydney
St. Vincent's Hospital Sydney
Australia, Sydney
Unsw Sydney
Carrat, Fabrice
Unknown Affiliation
Lusivika-Nzinga, Clovis
Unknown Affiliation
Degasperi, Elisabetta
Unknown Affiliation
Di Marco, Vito
Unknown Affiliation
Hou, Jinlin Ling
Unknown Affiliation
Howell, Jessica A.
Unknown Affiliation
Janjua, Naveed Z.
Unknown Affiliation
Kumada, Takashi
Unknown Affiliation
Lleo, Ana
Unknown Affiliation
Persico, M.
Unknown Affiliation
Lok, Anna Suk Fong
Unknown Affiliation
Wei, Lai
Unknown Affiliation
Nguyen, Mindie H.
Unknown Affiliation
Reig, Marìa Elisa
Unknown Affiliation
Shiha, Gamal Elsayed
Unknown Affiliation
Yu, Minglung
Unknown Affiliation
Statistics
Citations: 24
Authors: 18
Affiliations: 2
Identifiers
Doi:
10.1002/hep.32341
ISSN:
02709139
Research Areas
Infectious Diseases
Study Design
Cohort Study
Study Approach
Quantitative
Systematic review